{"article_title": "Lawsuit Alleges Price Gouging by Maker of Hepatitis Drug", "article_keywords": ["urged", "transportation", "state", "price", "companies", "gouging", "drug", "switch", "tack", "hepatitis", "transit", "usage", "alleges", "lawsuit", "maker", "struggled", "treatment"], "article_url": "http://www.wsj.com/articles/lawsuit-alleges-price-gouging-by-maker-of-hepatitis-drug-1418961024", "article_text": "Ever since Gilead Sciences began selling its Sovaldi hepatitis C treatment, there has been controversy over the price. State Medicaid directors have struggled to restrict usage. A congressional hearing was held. And at one point, the nation\u2019s biggest pharmacy benefit manager urged companies and health plans to switch to medicines made by rival companies once those drugs are approved.\n\nBut the Southeastern Pennsylvania Transportation Authority has decided on a different tack. The transit agency, which serves the greater...", "article_metadata": {"article.template": "snippet", "article.created": "2014-12-19T03:50:00.000Z", "article.section": "Business", "page.region": "na,us", "page.content.type": "Article", "twitter": {"domain": "wsj.com", "description": "Ever since Gilead Sciences began selling its Sovaldi hepatitis C treatment, there has been controversy over the high price. Last week, the transit agency that serves greater Philadelphia filed an unusual lawsuit claiming that Gilead is price gouging.", "creator": "@pharmalot", "image": {"src": "https://si.wsj.net/public/resources/images/BN-GC034_SOVALD_G_20141218153040.jpg", "alt": "Lawsuit alleges price gouging by maker of hepatitis C treatment", "identifier": "https://si.wsj.net/public/resources/images/BN-GC034_SOVALD_D_20141218153040.jpg"}, "title": "Lawsuit Alleges Price Gouging by Maker of Hepatitis Drug", "site": "@WSJ", "card": "summary_large_image"}, "al": {"ios": {"url": "wsj://launch?articleid=SB12265722269804043990704580345033831235208&headline=Lawsuit%20alleges%20price%20gouging%20by%20maker%20of%20hepatitis%20C%20treatment&weburl=http://www.wsj.com/articles/SB12265722269804043990704580345033831235208"}}, "page.site.product": "WSJ", "keywords": "drug prices,gilead sciences,hepatitis c,southeastern pennsylvania transportation authority,U.S. Department of Veterans Affairs,Southeastern Pennsylvania Transportation Authority,Gilead Sciences,GILD,Cigna,CI,Constantine Cannon,Ankur Kapoor,C. Scott Hemphill,Chris Bradbury,Gino Benedetti,Matt Salo,Nicholas Chimicles,corporate crime,legal action,regulation,government policy,new products,services,anti-competition issues,labor,personnel,new product approvals,corporate,industrial news,workplace discrimination,political,general news,society,community,discrimination,health,hepatitis,medical conditions,politics,international relations,domestic politics,social issues,medical treatments,procedures,government bodies,executive branch,veterans affairs department,biotechnology,pharmaceuticals,urban,commuter transit,urban mass transit systems,health care,life sciences,biopharmaceuticals,drugs,medication,road,rail transport,transportation,shipping", "news_keywords": "drug prices,gilead sciences,hepatitis c,southeastern pennsylvania transportation authority,U.S. Department of Veterans Affairs,Southeastern Pennsylvania Transportation Authority,Gilead Sciences,GILD,Cigna,CI", "article.headline": "Lawsuit alleges price gouging by maker of hepatitis C treatment", "cXenseParse": {"candybar": {"image": "https://si.wsj.net/public/resources/images/BN-GC034_SOVALD_E_20141218153040.jpg"}, "poptart": {"image": "https://si.wsj.net/public/resources/images/BN-GC034_SOVALD_D_20141218153040.jpg"}}, "description": "Ever since Gilead Sciences began selling its Sovaldi hepatitis C treatment, there has been controversy over the high price. Last week, the transit agency that serves greater Philadelphia filed an unusual lawsuit claiming that Gilead is price gouging.", "apple-itunes-app": "app-id=364387007,app-argument=wsj://launch?articleid=SB12265722269804043990704580345033831235208&headline=Lawsuit%20alleges%20price%20gouging%20by%20maker%20of%20hepatitis%20C%20treatment&weburl=http://www.wsj.com/articles/SB12265722269804043990704580345033831235208", "user.type": "nonsubscriber", "article.page": "Business", "page.content.format": "responsive", "article.summary": "Ever since Gilead Sciences began selling its Sovaldi hepatitis C treatment, there has been controversy over the high price. Last week, the transit agency that serves greater Philadelphia filed an unusual lawsuit claiming that Gilead is price gouging.", "page.site": "wsj", "testkeys": "B", "article.published": "2014-12-19T03:50:00.000Z", "dj.asn": "i-f264", "robots": "noarchive,noodp", "fb": {"app_id": 368513495882}, "article": {"publisher": "https://www.facebook.com/wsj", "embed_count": 1, "image_count": 1, "word_count": 783, "internal_link_count": 2}, "viewport": "width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=1.0, user-scalable=no", "page.section": "Article", "language": "en-US", "og": {"site_name": "WSJ", "description": "Ever since Gilead Sciences began selling its Sovaldi hepatitis C treatment, there has been controversy over the high price. Last week, the transit agency that serves greater Philadelphia filed an unusual lawsuit claiming that Gilead is price gouging.", "title": "Lawsuit Alleges Price Gouging by Maker of Hepatitis Drug", "url": "http://www.wsj.com/articles/lawsuit-alleges-price-gouging-by-maker-of-hepatitis-drug-1418961024", "image": {"width": 553, "identifier": "https://si.wsj.net/public/resources/images/BN-GC034_SOVALD_G_20141218153040.jpg", "height": 369}, "locale": "en_US", "type": "article"}, "author": "Ed Silverman", "article.access": "paid", "page.content.source": "WSJ Online Article", "article.origheadline": "Lawsuit Alleges Price Gouging by Maker of Hepatitis Drug", "article.type": "Business", "article.id": "SB12265722269804043990704580345033831235208", "user.exp": "default", "article.updated": "2014-12-19T03:50:00.000Z"}, "_id": "\"57477af36914bd0286fcad05\"", "article_summary": "Ever since Gilead Sciences began selling its Sovaldi hepatitis C treatment, there has been controversy over the price.\nAnd at one point, the nation\u2019s biggest pharmacy benefit manager urged companies and health plans to switch to medicines made by rival companies once those drugs are approved.\nState Medicaid directors have struggled to restrict usage.\nBut the Southeastern Pennsylvania Transportation Authority has decided on a different tack.\nThe transit agency, which serves the greater..."}